National Centre for Immunisation Research and Surveillance and University of Sydney Children's Hospital Westmead Clinical School
Sanjay is a medical graduate with postgraduate qualifications in community medicine and public health. He is an epidemiologist and a research fellow at Australia’s National Centre for Immunisation Research and Surveillance (NCIRS). Sanjay holds a conjoint academic appointment as Senior Lecturer in Children’s Hospital Westmead Clinical School of The University of Sydney. His PhD from The University of Sydney was on effectiveness of pneumococcal vaccinations in Australian children and epidemiology of pneumococcal disease in special risk groups. Sanjay’s work at NCIRS for over 10 years has primarily been in the area of evidence-based technical support for the development of immunisation policy and practice in Australia. Sanjay is a member of the national IPD surveillance working group.
Moderator of 1 Session
Session Type
Meet-the-Expert Session
Date
Tue, 21.06.2022
Session Time
13:30 - 14:30
Room
Grand Ballroom West
Chair(s)
Session Description
In this session we will present data from our respective countries on the main serotypes that are emerging to be dominant in the post higher valency vaccine use era (i.e. post 13vPCV/10vPCV) and discuss the interpretation of that data in terms of serotype replacement.
We will touch on definitions and views on the possible mechanisms of serotype replacement. We will also focus on changes in serotype 3 disease, what effect COVID-19 pandemic would have had on serotype profile of pneumococcal disease and the place of new higher valency PCVs becoming available now (such as 15vPCV and 20vPCV) in addressing replacement disease.
We believe that this session will help attendees in interpreting pneumococcal disease epidemiology following vaccine use and understand changes in serotype distribution in the context of replacement. There will be learnings from the data we will discuss that mainly reflect what occurred in countries with mature PCV programs for other settings that have introduced PCVs more recently and also those yet considering PCV use.
Please note: All MTE sessions are designed to encourage active learning and to concentrate on close interaction between audience and speakers. The MTE session organisers have provided at least 15 minutes for active discussions in their agenda.
We will touch on definitions and views on the possible mechanisms of serotype replacement. We will also focus on changes in serotype 3 disease, what effect COVID-19 pandemic would have had on serotype profile of pneumococcal disease and the place of new higher valency PCVs becoming available now (such as 15vPCV and 20vPCV) in addressing replacement disease.
We believe that this session will help attendees in interpreting pneumococcal disease epidemiology following vaccine use and understand changes in serotype distribution in the context of replacement. There will be learnings from the data we will discuss that mainly reflect what occurred in countries with mature PCV programs for other settings that have introduced PCVs more recently and also those yet considering PCV use.
Please note: All MTE sessions are designed to encourage active learning and to concentrate on close interaction between audience and speakers. The MTE session organisers have provided at least 15 minutes for active discussions in their agenda.